« Return to News | CROs/Service Providers

Venn Life Sciences and Encorium to merge

Wednesday, February 22, 2012 01:57 PM

Finland-based CRO Encorium Group and Venn Life Sciences, a provider of development consulting and resourcing services based in Dublin, Ireland, have agreed to merge.

The combined operation will be named Venn Life Sciences Limited, will be headquartered in Ireland and will have over 200 employees operating from over 20 locations worldwide.

The management team and board of the combined entity will be comprised of existing management of both companies. Leading the management team will be Sean Leech, Venn’s current CEO. The board will be led by Dr. Kai Lindevall, Encoriums’ current CEO.

“Our combined management, operational and project teams have many years of clinical and consulting experience in the various forms of clinical development models. This variation of experience will be a critical component to future success in the clinical outsourcing arena,” said Tony Richardson, executive chairman of Venn.

“I am pleased that the months of planning have yielded a successful outcome and one that will ensure continuity of business for our clients and employees,” said Dr. Lindevall.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.